Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMIX Autonomix Medical	$1.60 -3.0%	$1.82	$1.52 ▼ $46.00	$4.45M	-3.47	314,988 shs	38,690 shs
BLAC Bellevue Life Sciences Acquisition	$1.31 -9.7%	$1.46	$3.01 ▼ $13.40	$5.29M	-0.08	19,293 shs	122,498 shs
NUWE Nuwellis	$0.77 -8.8%	$0.93	$0.75 ▼ $8.79	$3.37M	0.51	968,713 shs	207,551 shs
NVIVQ Invivo Therapeutics	$0.37	$0.37	$0.00 ▼ $0.00	$1.15M	0.4	N/A	N/A

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMIX Autonomix Medical	+3.12%	-6.25%	-17.50%	-33.20%	-96.38%
BLAC Bellevue Life Sciences Acquisition	0.00%	+25.00%	+2.84%	-44.23%	-86.49%
NUWE Nuwellis	-3.05%	-8.94%	-20.28%	-31.30%	-90.79%
NVIVQ Invivo Therapeutics	0.00%	0.00%	0.00%	0.00%	+36,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMIX Autonomix Medical	3.2354 of 5 stars	3.5	4.0	0.0	0.0	2.7	1.7	1.3
BLAC Bellevue Life Sciences Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NUWE Nuwellis	2.5537 of 5 stars	3.5	3.0	0.0	0.0	2.7	0.0	1.3
NVIVQ Invivo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMIX Autonomix Medical	3.00	Buy	$16.50	931.25% Upside
BLAC Bellevue Life Sciences Acquisition	0.00	N/A	N/A	N/A
NUWE Nuwellis	3.00	Buy	$17.00	2,104.93% Upside
NVIVQ Invivo Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NVIVQ, BLAC, AMIX, and NUWE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/13/2025	NUWE Nuwellis	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/29/2025	AMIX Autonomix Medical	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00

(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMIX Autonomix Medical	N/A	N/A	N/A	N/A	$8.12 per share	N/A
BLAC Bellevue Life Sciences Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
NUWE Nuwellis	$8.79M	0.38	N/A	N/A	$18.40 per share	0.04
NVIVQ Invivo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMIX Autonomix Medical	-$15.43M	-$7.47	N/A	N/A	N/A	N/A	-212.48%	-161.13%	N/A
BLAC Bellevue Life Sciences Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
NUWE Nuwellis	-$20.21M	-$18.24	N/A	N/A	N/A	-169.54%	-28,159.25%	-207.24%	8/12/2025 (Estimated)
NVIVQ Invivo Therapeutics	-$10.49M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest NVIVQ, BLAC, AMIX, and NUWE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/29/2025	Q4 2025	AMIX Autonomix Medical	N/A	-$0.74	N/A	-$0.74	N/A	N/A
5/13/2025	Q1 2025	NUWE Nuwellis	-$0.45	-$0.69	-$0.24	-$0.69	$2.50 million	$1.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMIX Autonomix Medical	N/A	N/A	N/A	N/A	N/A
BLAC Bellevue Life Sciences Acquisition	N/A	N/A	N/A	N/A	N/A
NUWE Nuwellis	N/A	N/A	N/A	N/A	N/A
NVIVQ Invivo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMIX Autonomix Medical	N/A	5.31	5.31
BLAC Bellevue Life Sciences Acquisition	N/A	N/A	N/A
NUWE Nuwellis	N/A	2.03	1.34
NVIVQ Invivo Therapeutics	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMIX Autonomix Medical	10.78%
BLAC Bellevue Life Sciences Acquisition	55.30%
NUWE Nuwellis	3.13%
NVIVQ Invivo Therapeutics	12.32%

Insider Ownership

Company	Insider Ownership
AMIX Autonomix Medical	32.40%
BLAC Bellevue Life Sciences Acquisition	33.67%
NUWE Nuwellis	1.60%
NVIVQ Invivo Therapeutics	2.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMIX Autonomix Medical	1	2.78 million	1.67 million	N/A
BLAC Bellevue Life Sciences Acquisition	N/A	4.04 million	2.68 million	Not Optionable
NUWE Nuwellis	70	4.37 million	4.26 million	Not Optionable
NVIVQ Invivo Therapeutics	6	3.11 million	3.03 million	N/A

NVIVQ, BLAC, AMIX, and NUWE Headlines

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell
By Gabriel Osorio-Mazilli | May 30, 2025
View Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell
3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest Loser
By Leo Miller | May 13, 2025
View 3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest Loser
A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready
By Gabriel Osorio-Mazilli | May 12, 2025
View A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready

NVIVQ, BLAC, AMIX, and NUWE Company Descriptions

Autonomix Medical NASDAQ:AMIX

$1.60 -0.05 (-3.03%)

Closing price 03:59 PM Eastern

Extended Trading

$1.63 +0.03 (+1.87%)

As of 05:11 PM Eastern

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

Bellevue Life Sciences Acquisition NASDAQ:BLAC

$1.31 -0.14 (-9.66%)

As of 06/2/2025

Bellevue Life Sciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities in the healthcare industry. The company was incorporated in 2020 and is based in Bellevue, Washington. Bellevue Life Sciences Acquisition Corp. operates as a subsidiary of Bellevue Global Life Sciences Investors LLC.

Nuwellis NASDAQ:NUWE

$0.77 -0.07 (-8.76%)

Closing price 04:00 PM Eastern

Extended Trading

$0.81 +0.04 (+4.93%)

As of 04:46 PM Eastern

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

Invivo Therapeutics NASDAQ:NVIVQ

$0.37 0.00 (0.00%)

As of 07/26/2024

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time